A new publication involving terlipressin was released on July 25, 2026. The study, titled "Evaluation of Terlipressin and In-Hospital Mortality in the Treatment of Hepatorenal Syndrome-Acute Kidney Injury (HRS-AKI)," appeared in The Annals of Pharmacotherapy.
The publication addresses the use of terlipressin in patients with hepatorenal syndrome-acute kidney injury, a condition abbreviated as HRS-AKI. Terlipressin is an approved compound referenced in this evaluation.
No specific findings, outcomes, or data points from the study are detailed here beyond its title and publication venue. Readers interested in the full scope of the evaluation, including any reported associations with in-hospital mortality, are encouraged to consult the original article directly through the source listed.
This brief reports only the existence and bibliographic details of this publication as provided. It does not characterize or summarize the study's conclusions, methodology, or results. For additional background on terlipressin, including its approved uses and general profile, readers can consult the compound overview.